China Medicine Corporation
CHME · OTC
9/30/2010 | 6/30/2010 | 3/31/2010 | 12/31/2009 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | -0.02 | 0.14 | 0.05 |
| FCF Yield | -10.61% | -6.82% | 2.10% | 20.51% |
| EV / EBITDA | 13.89 | 11.47 | 38.24 | 16.48 |
| Quality | ||||
| ROIC | 1.34% | 2.32% | 0.73% | 15.43% |
| Gross Margin | 33.07% | 35.53% | 30.72% | 33.47% |
| Cash Conversion Ratio | -0.16 | -0.87 | 0.83 | -6.20 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.16% | 12.39% | 13.96% | 15.43% |
| Free Cash Flow Growth | -32.30% | -364.84% | -89.86% | 1,332.67% |
| Safety | ||||
| Net Debt / EBITDA | -1.60 | -0.97 | 0.19 | 1.99 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.00 | 2.85 | 1.98 | 4.98 |
| Cash Conversion Cycle | 126.91 | 141.29 | 196.13 | 107.58 |